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Matrix metalloproteinases (MMPs), a large family of calcium-dependent zinc-containing
endopeptidases, are involved in the tissue remodeling and degradation of the
extracellular matrix. MMPs are widely distributed in the brain and regulate various
processes including microglial activation, inflammation, dopaminergic apoptosis, blood-
brain barrier disruption, and modulation of α-synuclein pathology. High expression of
MMPs is well documented in various neurological disorders including Parkinson’s disease
(PD), Alzheimer’s disease (AD), Japanese encephalitis (JE), and Glaucoma. Although
potentially critical, the role of MMPs in neuronal disorders is under-investigated. The
present review summarizes the role of MMPs in neurodegeneration with a particular
emphasis on PD, AD, JE, and Glaucoma.
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Introduction
Matrix metalloproteinases (MMPs) are described as calcium-dependent zinc endopeptidases. The
roles of MMPs have been demonstrated in extracellular matrix (ECM) degradation and remodeling
of tissues. MMPs specifically act on the different segments of ECM like collagen, gelatin, and elastin.
MMPs were first discovered in 1962, and interstitial collagenase protein that cleaves collagen was
initially isolated in 1968 (Gross and Lapiere, 1962; Eisen et al., 1968). MMPs are classified into four
primary subgroups on the premise of domain structure: collagenases, gelatinases, stromelysins,
and film sort (MT)-MMPs. Collagenases degrade triple helical fibrillary collagens, which are the
fundamental segments of bone and ligament. Gelatinases (MMP-2 and MMP-9) are included in
angiogenesis and neurogenesis by corrupting basal lamina molecules and subsequently leading to
the cell death. Stromelysins (MMP-3, MMP-10, MMP-11, and MMP-7) are small proteases that
degrade segments of the extracellular matrix. MT-MMPs activate a few proteases and development
components at the cell surface. As of late, an expanding measure of proof proposes that MMPs may
assume an essential part in the pathogenesis of various neurodegenerative disorders (Forsyth et al.,
1999; Lorenzl et al., 2002, 2003; Yong et al., 2007; Candelario-Jalil et al., 2009; Choi et al., 2011; Shin
et al., 2012). Although potentially imperative, the role of MMPs in neuronal disorders is under-
investigated. In this brief review, we have made an attempt to shed a light on the role of MMPs
in neurological disorders with a particular emphasis on Parkinson’s disease, Alzheimer’s disease,
Glaucoma, and Japanese encephalitis.
MMPs in Nervous System
The mammalian CNS contains more than 10 different types of MMPs that can be detected at
mRNA and protein levels (Pagenstecher et al., 1998; Ulrich et al., 2005; Fujioka et al., 2012). The
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studies have demonstrated thatMMPs participate in the neuronal
development and have ability to change the response to injury
and neurological disease (Pagenstecher et al., 1998; Yong et al.,
2001; Ulrich et al., 2005; Yong, 2005; Fujioka et al., 2012).
Their expression profile varies according to the developmental
program. Analysis has shown a developmental regulation of
several of several MMPs including MMP-2, -9, -11, -12, -13,
-14, -15, and -24, whereas certain MMPs for example MMP-
3, -7, and -10 don’t respond to these signals and remain
unchanged during neuronal development (Pagenstecher et al.,
1998; Ulrich et al., 2005; Yong, 2005; Fujioka et al., 2012).
Remarkably, the extensive research is done on the role of two
secreted MMPs, MMP-2, and MMP-9 since they are detected
relatively easily in central nervous system (CNS). Both MMP-2
and MMP-9 are mostly detected in the cortex and cerebellum.
MMP-9 is also detected in the hippocampus suggesting its
critical role in neuronal biology (Pagenstecher et al., 1998;
Ulrich et al., 2005; Yong, 2005; Fujioka et al., 2012). Genetic
ablation of specific MMPs altogether influences the injury and
pathology, therefore, essentially mediates neuronal disorders,
including learning and memory (van Den Steen et al., 2002;
Ethell and Ethell, 2007; Hu et al., 2007). In addition, MMPs likely
intercede the structural modifications of dendritic spines and also
axon/dendrite structures (Ethell and Ethell, 2007; Hu et al., 2007).
Role of MMPs in Parkinson’s Disease
Parkinson’s malady (PD) is the most widely recognized
neurodegenerative disorder described by motor symptoms
including resting tremor, unbending nature, bradykinesia, and
postural unsteadiness due to specific loss of dopaminergic
neurons in the substantia nigra pars compacta. It is likewise a late
onset disease and often noticed in the individuals over the age of
50 years. It is widely recognized nervous system disorder of the
elderly. Hereditary, ecological, and age-related variables assume
decisive parts in the loss of dopaminergic neurons and glial cells
that may prompt Parkinson’s disease (Lindvall and Kokaia, 2006).
It is now well established that the expression of several
MMPs and their inhibitors are altered in the substantia nigra
(SN) of brain of patient with PD proposing the urgent need
for further investigation of the role of MMPs in PD (Lorenzl
et al., 2002). MMPs have been recommended to contribute to the
pathophysiology of PD by microglial activation, inflammation,
dopaminergic apoptosis, blood-brain barrier (BBB) disruption
and modulation of α-synuclein pathology by cleavage (Kim et al.,
2005; Choi et al., 2008; Joo et al., 2010; Kim and Hwang, 2011).
MMP-3, a zinc-dependent proteolytic enzyme that is broadly
dispersed in the brain and can activate select pro-MMPs along
with the cleavage of cell adhesion molecules, chemokines, and
cytokines, is likewise reported in PD pathogenesis, especially
in DA neuronal death, BBB damage, and neuroinflammation
(Kim and Joh, 2006; Kim and Hwang, 2011; Van Hove et al.,
2012a,b; Chung et al., 2013). The role of MMP-9 has also been
implicated in PD, and its higher promoter activity due to C(-
1562)T polymorphism was observed in a recent study (He et al.,
2013). Furthermore, MMP1 has also been shown to be involved
in PD pathogenesis in a case-control study by Gupta et al.
demonstrating lower levels of MMP-1 in PD patients contrasted
with the healthy controls. The study further stated a poor but
statistically significant correlation between MMP-1 level and
disease duration (Gupta et al., 2013).
Role of MMPs in Alzheimer’s Disease
Alzheimer’s disease (AD) is characterized by spasms of the
neurons leading to the loss of memory and behavioral changes.
It is a late-onset disease, and manifestations show up mostly after
the age of 60 years resulting in the progressive loss ofmemory and
speculation abilities, and inevitably the patients can’t perform
even easiest assignments. AD is also suggested to be the major
cause of dementia (Upadhyay et al., 2014). Estimates vary, but
experts suggest that as many as 5.1 million Americans may
have Alzheimer’s disease (Upadhyay et al., 2014). Both hereditary
and environmental components add to AD pathogenesis and
an exclusion criterion (by eliminating the likelihood of different
reasons for dementia) is taken into account alongside considering
significant manifestations of AD for its diagnosis (Upadhyay
et al., 2014).
Neuropathological hallmarks of Alzheimer’s disease include
neuronal tangles and amyloid plaques (Laferla et al., 2007;
Rosenberg, 2009). Deposition of improperly processed amyloid
is thought to be a main factor in the pathophysiology of AD.
The role of MMPs in CNS pathology is now well known and
different studies have demonstrated the significance of MMPs
for the pathophysiological process amid AD. These MMPs
are essentially included in the formation and clearance of the
amyloid-β peptides (Aβ) and discovered to be induced by the
amyloid molecules in blood vessels, astrocytes, and microglia
(Yan et al., 2006; Yin et al., 2006; Walsh et al., 2007). The
inflammatory response, such as activation of microglia and
astrocytes in response to the deposition of Aβ in tissues around
the plaques, might contribute to neuronal death in AD (Selkoe,
2008). The increase in expression of MMPs in brain tissues and
blood of patients with AD is probably part of the inflammatory
response. Furthermore, growing body of knowledge suggests the
dual role of MMPs in AD pathogenesis. At one hand it directly
degrade Aβ resulting in reduction in Aβ deposit (Yan et al.,
2006; Miners et al., 2008); then again, these could contribute
to brain parenchymal destruction when induced by Aβ in
microglia, astrocytes or vascular smooth muscle cells. These data
clearly indicate the involvement of MMPs in the pathogenesis
of AD.
Role of MMPs in Japanese Encephalitis
Japanese encephalitis (JE) that commonly affects children is
caused by a single-stranded RNA virus, JE virus (JEV) results
in severe neurological disorders (Kalita et al., 2007; Misra
et al., 2009). It infects the central nervous system leading
to acute encephalitis occurring in a broad spectrum of the
Asian subcontinent (Kumar et al., 2009a). The transmission
of JEV in humans occurs mostly by mosquito vector (Culex
tritaeniorhynchus). JEV infection causes severe damage to
neurons in the various parts of the brain (Kumar et al., 2009a).
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Additionally, JE infection has been reported to impair the
balanced dynamic actions of oxidant and antioxidant systems in
rats (Kumar et al., 2009b).
Although, the exact mechanism of neuronal cell death in JE is
unclear, some studies established the role of MMPs in neuronal
cell death. A recent study suggests that during JEV infection,
the expression of MMPs (MMP-2, -7, -9) and TIMPs (TIMP-1
and -3) are greatly increased and can contribute to the disease
severity in CNS (Shukla et al., 2012). Furthermore, It has been
shown that the induction of MMP-9 is most likely due to AP-1
activation triggered by ROS/c-Src/PDGFR/PI3K/Akt/MAPKs
pathway following JEV infection (Tung et al., 2010; Yang et al.,
2012). Shukla et al. demonstrated higher concentrations of
MMP-2, TIMP-2, and TIMP-3 in cerebrospinal fluid (CSF)
and serum of children with JEV as compared with disease
control (DC) (Shukla et al., 2013). They also observed a higher
concentration of MMP-9 and MMP-7 in the serum of JEV
patients when compared with DC and healthy control but not
in CSF (Shukla et al., 2013).
Role of MMPs in Glaucoma
Glaucoma, a neurodegenerative disease, is a group of ocular
disorders with multi-factorial etiology. It is the second leading
cause of blindness after cataract in the world. Over 60 million
people are affected worldwide while more than 2 million
individuals are affected in the United States. Mainly it occurs
in two forms- open angle glaucoma and closed angle glaucoma.
Open angle glaucoma (also known as primary open angle
glaucoma) is the commonest form of glaucoma where retinal
ganglion cells (RGCs) degeneration progress slowly without
showing any symptom at early stage while vision loss occurs
quickly in later form of glaucoma. The most prevalent and major
risk factor is elevated intraocular pressure (IOP) is the primary
parameter to be used in the diagnosis of disease. Glaucoma is
associated with optic nerve degeneration and RGCs death by
apoptosis leading to visual field loss (Quigley, 1999; Tatton et al.,
2001; Halpern and Grosskreutz, 2002). Several environmental,
genetic and age-related factors contribute to the onset of the
disease (Leske et al., 2007; Calkins and Horner, 2012).
Despite several efforts, themechanism of RGC and optic nerve
degeneration is not clearly understood. However, some studies
have been established the role of MMPs in the pathophysiology of
glaucoma. MMPs, major matrix degrading enzymes are involved
in remodeling of ECM of the trabecular meshwork to maintain
stable aqueous humor outflow resistance and IOP (De Groef
et al., 2013). Besides the anterior segment of the eyes, MMPs
are also involved in the regulation of retinal cell death. MMP-9
is reported to promote the RGC death by abolishing integrin-
mediated survival signaling pathways via laminin degradation
(Guo et al., 2005; Halfter et al., 2005; Santos et al., 2012). The
role of MMPs in the regulation of outflow resistance has also
been studied in steroid-induced glaucoma (SIG), a form of
glaucoma that resembles with primary open angle glaucoma. SIG
is caused by the potent use of glucocorticoids which results in a
decreased trabecular outflow leading to increased IOP (Kumar
et al., 2013b). The up-regulation of several MMPs specifically
MMP-2, MMP-9, and MMP-13 are reported in steroid induced
mice model of glaucoma (Kumar et al., 2013a). In another
study, mRNA expression of MMP-1 (but not MMP-2, MMP-
9, and MMP-13) was found to be significantly up-regulated in
steroid induced sheep model of glaucoma. (Gerometta et al.,
2013).
Conclusion
Our understanding about the role of MMPs in neurological
disorders including Glaucoma and JE has increased enormously
during past few years. Nevertheless, the imperative role of
MMPs in the pathogenesis of the elderly neurological diseases,
such as AD, PD and so forth needs further and extensive
investigation. Since the role of MMPs in the regulation of the
pathological alterations in the blood vessels and ECM around
cells is unfolding, the need of the hour is to investigate these in
the clinics. It is remarkable that these processes determine the
fate of cell survival and permeability of BBB. Targeting these
events could be of great therapeutic value, and it is necessary
to explore the role of MMPs more widely and wisely in order
to develop new potential strategies for the cure of neurological
disorders.
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